Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.
Luna ColagrossiLucas E HermansRomina SalpiniDomenico Di CarloSuzan D PasMarta AlvarezZiv Ben-AriGreet BolandBianca BruzzoneNicola CoppolaCarole Seguin-DevauxTomasz DydaFederico GarciaRolf KaiserSukran KöseHenrik KrarupIvana LazarevicMaja M LunarSarah MaylinValeria MicheliOrna MorSimona ParaschivDimitros ParaskevisMario PoljakElisabeth Puchhammer-StöcklFrançois SimonMaja StanojevicKathrine Stene-JohansenNijaz TihicPascale TrimouletJens VerheyenAdriana VinceSnjezana Zidovec LepejNina WeisTülay YalcinkayaCharles A B BoucherAnnemarie M J WensingCarlo F PernoValentina Svichernull nullPublished in: BMC infectious diseases (2018)
Immune-escape mutations and stop-codons develop in a large fraction of NA-exposed patients from Europe. This may represent a potential threat for horizontal and vertical HBV transmission also to vaccinated persons, and fuel drug-resistance emergence.